We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effect of Peroxisome Proliferator-Activated Receptor Agonists on Serum Inflammatory Markers in Diabetic Rats.
- Authors
Khazaei, Majid; Tahergorabi, Zoya; Salehi, Ensieh
- Abstract
Background: Inflammation had a key role in several pathological conditions including atherosclerosis. Previous studies indicated that the proxisome proliferator-activated receptors (PPAR) are involved in numerous physiological and pathological conditions. The aim of this study was to investigate the effect of PPAR agonists including PPARα (fenofibrate), PPARβ/δ (GW0742), PPARγ (rosiglitazone) and pan PPAR (bezafibrate) administration on serum high-sensitive C-reactive protein (hsCRP) and interleukine-6 (IL-6) in male diabetic rats. Methods: The male Wistar rats were received streptozotocin for induction of type I diabetes. Then, they were randomly divided into five groups: diabetic, diabetic + fenofibrate (100 mg/kg/day; gavage), diabetic + GW0742 (1 mg/kg/day, subcutaneous), diabetic + rosiglitazone (8 mg/kg/day; gavage) and diabetic + bezafibrate (400mg/kg/day; gavage). After 21 days, the serum levels of hsCRP and IL-6 were measured using the enzyme-linked immunosorbent assay (ELISA) kits. Findings: Administration of different PPAR agonists did not alter serum hsCRP and IL-6 concentrations in diabetic animals. Conclusion: It seems that changes of serum inflammatory markers are not responsible for effects of PPARs agonist in atherosclerosis process and other mechanisms should be studied.
- Subjects
PEROXISOMES; PEOPLE with diabetes; LABORATORY rats; ATHEROSCLEROSIS; INTERLEUKIN-6; STREPTOZOTOCIN
- Publication
Journal of Isfahan Medical School, 2014, Vol 32, Issue 277, p1
- ISSN
1027-7595
- Publication type
Article